Trimic

Candidal vulvovaginitis, bacterial vaginosis, trichomonal vaginitis & mixed vag infections.

Treatment of vaginitis Adult & elderly (>65 yr) Insert vag supp at night & in the morning for 7 days, or insert 1 vag supp at night for 14 days. Vaginitis resistant to other treatments or recurrent vaginitis Insert 1 vag supp at night & in the morning for 14 days.

Hypersensitivity. Severe liver problems, nervous system diseases, disturbances in hematopoiesis.

Patients w/ liver impairment including porphyria, diseases of the nervous system & hematopoiesis. Do not take alcohol during the therapy & for at least 2 days after the end of a course of treatment. May interact w/ certain rubber or latex products eg, those used in vag contraceptive diaphragms or condoms. Discontinue breastfeeding during therapy, may start breastfeeding again 24-48 hr after the end of therapy.

Abdominal pain or cramp, metallic taste, constipation, dry mouth, seldom diarrhea, lack of appetite, vomiting, nausea; decrease of WBC; cramps; headache, movement disorders, dizziness, mental changes, peripheral neuropathy after overdose or long period of usage; vag irritation (burning, itching); rash.

Metronidazole: Disulfiram-like reaction w/ alcohol. Increase risk of cardiotoxicity (QT prolongation, Torsade de pointes, cardiac arrest) w/ amiodarone. Increases plasma conc of astemizole & terfenadine. CNS related effects (eg, psychotic reactions) w/ disulfiram. Increased blood levels of phenytoin. Decreased blood levels w/ phenobarb. Increased blood levels & toxicity of fluorouracil & lithium. Increased blood conc of carbamazepine. Increased effect of anticoagulants. Increased risk of cyclosporine toxicity. Increased blood levels & risk of neurologic side effects w/ cimetidine. Miconazole: Increased bleeding risk w/ acenocoumarol, anisindione, dicumarol, phenindione, phenprocoumon, warfarin. Increases plasma conc of astemizole, cisapride & terfenadine. Increases phenytoin toxicity risk (ataxy, hyperlexia, nystagmus, tremor). Increase or prolonged opioid effects (CNS depression, resp depression) w/ fentanyl. Increased hypoglycemic action of glimepiride. Decreased metabolism of carbamazepine. Increased plasma conc or exposure to oxybutinin. Increased plasma conc & reduction clearance of oxycodone. Increased cardiotoxicity risk (QT prolongation, torsades de pointes, cardiac arrest) w/ pimozide. Increased risk of cyclosporine toxicity (renal dysfunction, cholestasis, parasthesias). Increased bioavailability of tolterodine in patients deficient w/ CYP450 2D6 activity. Increased trimetrexate toxicity (bone marrow suppression, renal & hepatic dysfunction & GI ulceration). Do not use w/ barrier contraceptives eg, condoms as may lead to breaking of rubber.

Preparations for Vaginal Conditions

G01AF20 - combinations of imidazole derivatives ; Belongs to the class of imidazole derivative antiinfectives. Used in the treatment of gynecological infections.

Rx